CG 400549

Drug Profile

CG 400549

Alternative Names: CG400549; Enoyl reductase inhibitors - CrystalGenomics; ERCG 0549; FabI inhibitor (CG400549) - CrystalGenomics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CrystalGenomics
  • Class Antibacterials; Pyridines; Small molecules; Thiophenes
  • Mechanism of Action Enoyl-ACP reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Bacterial infections

Highest Development Phases

  • Phase II Methicillin-resistant Staphylococcus aureus infections
  • No development reported Staphylococcal infections; Vancomycin-resistant Staphylococcus aureus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections(In volunteers) in Europe (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Vancomycin-resistant-Staphylococcus-aureus-infections(In volunteers) in Europe (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top